These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11400244)

  • 21. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
    Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
    J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
    Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ; Fer M; Su FM; Breitz H; Thompson J; Goodgold H; Cain J; Heaps J; Weiden P
    Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues.
    Maraveyas A; Myers M; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1020-7. PubMed ID: 7866985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma.
    Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M
    Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL; Breitz HB; Seiler CA; Bjorn MJ; Ratliff BA; Mallett R; Beaumier PL; Appelbaum JW; Fritzberg AR; Salk D
    J Nucl Med; 1993 Dec; 34(12):2111-9. PubMed ID: 8254397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
    Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
    Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model.
    Wang SX; Bao A; Herrera SJ; Phillips WT; Goins B; Santoyo C; Miller FR; Otto RA
    Clin Cancer Res; 2008 Jun; 14(12):3975-83. PubMed ID: 18559620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
    Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.